Cardior

News

Novo Nordisk microRNA drug fluffs its lines in heart failure

A microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure.

R&D

Partner Content

Novo Nordisk seeks to target heart disease with Cardior acqu...

Cardior CSO will speak at the Oligonucleotide Therapeutics and Delivery conference following announcement of a buyout by Novo Nordisk to enhance their

News

Novo Nordisk’s head of development Martin Holst Lange

Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure

R&D

JP Morgan 2023 – Claudia Ulbrich

Last month, pharmaphorum sat down with Claudia Ulbrich, CEO of Germany-based Cardior.

Novo Nordisk microRNA drug fluffs its lines in heart failure

Novo Nordisk seeks to target heart disease with Cardior acqu...

Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

JP Morgan 2023 – Claudia Ulbrich

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

Cardior

Editor's Picks